BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23370223)

  • 1. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo.
    Cochonneau D; Terme M; Michaud A; Dorvillius M; Gautier N; Frikeche J; Alvarez-Rueda N; Bougras G; Aubry J; Paris F; Birklé S
    Cancer Lett; 2013 Jun; 333(2):194-204. PubMed ID: 23370223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
    Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
    PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.
    Fleurence J; Cochonneau D; Fougeray S; Oliver L; Geraldo F; Terme M; Dorvillius M; Loussouarn D; Vallette F; Paris F; Birklé S
    Oncotarget; 2016 Jul; 7(27):41172-41185. PubMed ID: 27172791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
    Fleurence J; Bahri M; Fougeray S; Faraj S; Vermeulen S; Pinault E; Geraldo F; Oliver L; Véziers J; Marquet P; Rabé M; Gratas C; Vallette F; Pecqueur C; Paris F; Birklé S
    Int J Cancer; 2020 Jan; 146(2):424-438. PubMed ID: 31241171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
    Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
    Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
    PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Cheung NK; Modak S
    Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
    Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
    Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting
    Fleurence J; Fougeray S; Bahri M; Cochonneau D; Clémenceau B; Paris F; Heczey A; Birklé S
    J Immunol Res; 2017; 2017():5604891. PubMed ID: 28154831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibody to tumor-associated ganglioside GD2.
    Katano M; Saxton RE; Irie RF
    J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular evidence of anti-leukemia activity of gypenosides on human myeloid leukemia HL-60 cells in vitro and in vivo using a HL-60 cells murine xenograft model.
    Lin JJ; Hsu HY; Yang JS; Lu KW; Wu RS; Wu KC; Lai TY; Chen PY; Ma CY; Wood WG; Chung JG
    Phytomedicine; 2011 Sep; 18(12):1075-85. PubMed ID: 21596541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
    Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis.
    Horwacik I; Rokita H
    Apoptosis; 2015 May; 20(5):679-88. PubMed ID: 25673107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft.
    Katano M; Saxton RE; Tsuchida T; Irie RF
    Jpn J Cancer Res; 1986 Jun; 77(6):584-94. PubMed ID: 3089993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
    Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
    Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.